Simon Ermakov, MD
Cardiovascular Disease (Cardiology) · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ermakov’s office at (650) 691-6174 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A134064 · Current
Licensed to practise in California · since 2015 · expires 2027-01-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$225,727
Medicare paid this office $225,727 for 1,178 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 292 | $54,421 | $116 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 189 | $36,738 | $189 |
| New patient visit (45+ min) | 172 | $24,199 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $18,543 | $105 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 28 | $12,501 | $446 |
See all 28 services
| Return visit (30+ min) | 292 | $54,421 | $116 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 189 | $36,738 | $189 |
| New patient visit (45+ min) | 172 | $24,199 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $18,543 | $105 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 28 | $12,501 | $446 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 47 | $10,753 | $229 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 145 | $8,687 | $58 |
| Long return visit (40+ min) | 39 | $7,844 | $171 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $6,122 | $113 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 12 | $5,648 | $471 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 381 | $5,105 | $13 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 261 | $4,821 | $15 |
| Critical care, first 30-74 minutes | 14 | $4,100 | $186 |
| Ultrasound of heart with probe in esophagus, with report | 34 | $3,403 | $95 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 110 | $2,409 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 35 | $2,123 | $59 |
| Programming of dual lead pacemaker system | 22 | $1,714 | $78 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 32 | $1,447 | $21 |
| Heart rhythm recording of continous external ekg over 8-15 days | 110 | $1,420 | $13 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 29 | $1,412 | $22 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 27 | $1,194 | $44 |
| 3d radiographic procedure with computerized image postprocessing | 32 | $1,150 | $34 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 30 | $557 | $19 |
| Ultrasound of heart blood flow, valves and chambers | 33 | $542 | $16 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 30 | $358 | $12 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $316 | $10 |
| Injection, regadenoson, 0.1 mg | 13 | $161 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 33 | $94 | $3 |
Procedures Medicare counted
| Pacemaker insertion or repair | 30 | More than 79% of doctors who do this |
Who their Medicare patients are
1,178 Original Medicare patients in 2024. Average age 78 · Under 65 2% · 85 and older 21% · Women 53% · Also on Medicaid 16% · Health risk score 1.19. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 33% · Atrial fibrillation 31% · Diabetes 29% · Chronic kidney disease 28% · Heart failure 23% · Cancer 21% · Depression 17% · COPD 13% · Stroke 11% · Dementia 8%.
The office billed $1,006,036, Medicare allowed $300,485 and paid $225,727; for 2,908 services of 51 kinds; $161 of it was for drugs given in the office and $225,566 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,178 | 2,908 | 78 | 1.19 | $1,006,036 | $225,727 |
| 2023 | 1,056 | 2,158 | 78 | 1.16 | $799,682 | $183,356 |
| 2022 | 488 | 975 | 78 | 1.37 | $363,223 | $90,607 |
| 2021 | 75 | 96 | 69 | 2.59 | $14,428 | $3,373 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 30 services
| Return visit (30+ min) | 159 | $29,713 | $117 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 122 | $23,574 | $184 |
| New patient visit (45+ min) | 126 | $18,134 | $144 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 67 | $14,952 | $223 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 26 | $12,323 | $474 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $12,161 | $106 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 170 | $10,656 | $60 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 17 | $7,334 | $431 |
| Long return visit (40+ min) | 36 | $6,532 | $159 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 397 | $5,359 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $4,422 | $113 |
| Removal and replacement of dual lead permanent pacemaker | 14 | $3,949 | $282 |
| Injection, regadenoson, 0.1 mg | 23 | $3,795 | None |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 24 | $3,658 | $76 |
| New patient visit (60+ min) | 17 | $3,299 | $194 |
| Ultrasound of heart with probe in esophagus, with report | 33 | $3,157 | $93 |
| New patient visit (30+ min) | 25 | $2,460 | $98 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 41 | $2,430 | $59 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 97 | $2,099 | $21 |
| Programming of dual lead pacemaker system | 15 | $1,311 | $82 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 29 | $1,275 | $44 |
| Heart rhythm recording of continous external ekg over 8-15 days | 97 | $1,189 | $12 |
| 3d radiographic procedure with computerized image postprocessing | 16 | $584 | $34 |
| Ultrasound of heart blood flow, valves and chambers | 28 | $466 | $16 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 13 | $397 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 13 | $374 | $25 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 17 | $360 | $21 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 17 | $225 | $13 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $193 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 27 | $78 | $3 |
2022: 18 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 69 | $14,057 | $204 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 22 | $10,739 | $488 |
| Return visit (30+ min) | 54 | $10,211 | $123 |
| New patient visit (45+ min) | 47 | $7,052 | $150 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 23 | $5,669 | $246 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $5,004 | $89 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 77 | $4,950 | $63 |
| Injection, regadenoson, 0.1 mg | 20 | $3,862 | None |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 22 | $3,838 | $87 |
| Long return visit (40+ min) | 17 | $3,263 | $172 |
| New patient visit (60+ min) | 14 | $2,911 | $208 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 179 | $2,461 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 26 | $1,602 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,573 | $112 |
| Short return visit (20+ min) | 12 | $1,483 | $87 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 39 | $932 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 39 | $587 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 19 | $174 | $6 |
2021: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 53 | $427 | $7 |
Medicaid work
$3,280 in 2024
Medicaid paid $3,280 for 419 billed services this clinician did in 2024, up to 86 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 325 | $1,512 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 22 | $1,105 |
| Return visit (30+ min) | 47 | $349 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 25 | $313 |
| 2024 | 419 | 4 | 86 | $3,280 |
| 2023 | 442 | 4 | 96 | $3,703 |
| 2022 | 162 | 2 | 57 | $153 |
| 2021 | 348 | 1 | 55 | $557 |
| 2020 | 253 | 1 | 37 | $276 |
| 2019 | 59 | 1 | 27 | $16 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 16 | $1,395 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 341 | $1,075 |
| Return visit (30+ min) | 50 | $854 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 35 | $379 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 148 | $153 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 14 | $0 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 348 | $557 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 253 | $276 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 59 | $16 |
Drugs they prescribed that Part D paid
$519,789
Pharmacies billed $519,789 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,296) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,905 generic and 391 brand-name prescriptions · $519,789 in drug cost · 35 antibiotic prescriptions to 30 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 212 | $267,733 | $1,263 |
| Jardiance | 79 | $109,294 | $1,383 |
| Repatha Sureclick | 27 | $41,579 | $1,540 |
| Entresto | 26 | $36,088 | $1,388 |
| Xarelto | 11 | $14,685 | $1,335 |
See all 35 drugs
| Eliquis | 212 | $267,733 | $1,263 |
| Jardiance | 79 | $109,294 | $1,383 |
| Repatha Sureclick | 27 | $41,579 | $1,540 |
| Entresto | 26 | $36,088 | $1,388 |
| Xarelto | 11 | $14,685 | $1,335 |
| Icosapent Ethyl | 18 | $8,387 | $466 |
| Metoprolol | 217 | $3,493 | $16 |
| Rosuvastatin | 193 | $3,396 | $18 |
| Atorvastatin | 255 | $2,318 | $9 |
| Valsartan | 45 | $1,874 | $42 |
| Nitroglycerin | 30 | $1,406 | $47 |
| Ezetimibe | 43 | $1,255 | $29 |
| Amlodipine Besylate | 196 | $1,116 | $6 |
| Diltiazem 24hr Er (Cd) | 32 | $1,110 | $35 |
| Olmesartan Medoxomil | 49 | $940 | $19 |
| Carvedilol | 67 | $713 | $11 |
| Lisinopril | 76 | $682 | $9 |
| Losartan | 77 | $655 | $9 |
| Ranolazine Er | 17 | $614 | $36 |
| Isosorbide Mononitrate Er | 44 | $562 | $13 |
| Spironolactone | 63 | $468 | $7 |
| Amiodarone | 25 | $437 | $17 |
| Digoxin | 20 | $404 | $20 |
| Furosemide | 71 | $384 | $5 |
| Clopidogrel | 28 | $330 | $12 |
| Flecainide Acetate | 15 | $329 | $22 |
| Torsemide | 14 | $231 | $17 |
| Hydrochlorothiazide | 55 | $221 | $4 |
| Hydralazine | 28 | $210 | $7 |
| Simvastatin | 21 | $141 | $7 |
| Benazepril | 11 | $106 | $10 |
| Propranolol | 11 | $87 | $8 |
| Metoprolol | 20 | $72 | $4 |
| Cephalexin | 25 | $68 | $3 |
| Atenolol | 12 | $27 | $2 |
Year by year
| 2024 | 2,296 | 415 | 0% (0) | 17% | $519,789 |
| 2023 | 1,194 | 270 | 0% (0) | 13% | $233,206 |
| 2022 | 1,024 | 271 | 0% (0) | 18% | $136,822 |
| 2021 | 831 | 235 | 0% (0) | 24% | $110,205 |
| 2020 | 344 | 96 | 0% (0) | 18% | $39,884 |
| 2019 | 72 | 30 | 0% (0) | 26% | $7,867 |
| 2018 | 43 | None | 0% (0) | 26% | $3,467 |
| 2017 | 39 | 11 | 0% (0) | None | $1,047 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Eliquis | 92 | $116,313 | $1,264 |
| Jardiance | 32 | $49,593 | $1,550 |
| Icosapent Ethyl | 20 | $7,810 | $391 |
| Rosuvastatin | 94 | $3,117 | $33 |
| Metoprolol | 134 | $2,715 | $20 |
| Atorvastatin | 142 | $1,842 | $13 |
| Valsartan | 18 | $1,694 | $94 |
| Ezetimibe | 22 | $1,608 | $73 |
| Diltiazem 24hr Er (Cd) | 21 | $1,534 | $73 |
| Carvedilol | 47 | $721 | $15 |
| Amlodipine Besylate | 93 | $668 | $7 |
| Hydralazine | 18 | $602 | $33 |
| Isosorbide Mononitrate Er | 25 | $564 | $23 |
| Spironolactone | 47 | $529 | $11 |
| Losartan | 36 | $468 | $13 |
| Furosemide | 59 | $454 | $8 |
| Torsemide | 16 | $411 | $26 |
| Clopidogrel | 25 | $404 | $16 |
| Chlorthalidone | 11 | $357 | $32 |
| Lisinopril | 45 | $311 | $7 |
| Nitroglycerin | 16 | $246 | $15 |
| Metoprolol | 20 | $215 | $11 |
| Atenolol | 12 | $161 | $13 |
| Cephalexin | 17 | $103 | $6 |
| Simvastatin | 16 | $91 | $6 |
| Hydrochlorothiazide | 12 | $37 | $3 |
2022: 25 drugs
| Eliquis | 51 | $47,086 | $923 |
| Jardiance | 29 | $23,953 | $826 |
| Entresto | 14 | $17,421 | $1,244 |
| Pradaxa | 25 | $16,758 | $670 |
| Xarelto | 12 | $10,137 | $845 |
| Metoprolol | 151 | $2,625 | $17 |
| Atorvastatin | 119 | $1,474 | $12 |
| Hydralazine | 19 | $1,235 | $65 |
| Amiodarone | 28 | $1,093 | $39 |
| Rosuvastatin | 31 | $749 | $24 |
| Ezetimibe | 17 | $618 | $36 |
| Sotalol | 17 | $560 | $33 |
| Ranolazine Er | 12 | $546 | $45 |
| Furosemide | 60 | $525 | $9 |
| Torsemide | 17 | $522 | $31 |
| Amlodipine Besylate | 46 | $421 | $9 |
| Losartan | 36 | $419 | $12 |
| Metoprolol | 47 | $395 | $8 |
| Carvedilol | 42 | $378 | $9 |
| Lisinopril | 38 | $373 | $10 |
| Clopidogrel | 14 | $296 | $21 |
| Isosorbide Mononitrate Er | 24 | $279 | $12 |
| Spironolactone | 26 | $195 | $7 |
| Cephalexin | 15 | $111 | $7 |
| Hydrochlorothiazide | 16 | $108 | $7 |
2021: 20 drugs
| Eliquis | 47 | $31,171 | $663 |
| Pradaxa | 42 | $30,423 | $724 |
| Jardiance | 23 | $11,111 | $483 |
| Metoprolol | 116 | $2,366 | $20 |
| Amiodarone | 41 | $1,508 | $37 |
| Atorvastatin | 68 | $956 | $14 |
| Sotalol | 25 | $772 | $31 |
| Furosemide | 60 | $717 | $12 |
| Ranolazine Er | 14 | $706 | $50 |
| Flecainide Acetate | 12 | $632 | $53 |
| Torsemide | 16 | $627 | $39 |
| Hydralazine | 11 | $605 | $55 |
| Losartan | 47 | $532 | $11 |
| Lisinopril | 36 | $453 | $13 |
| Metoprolol | 36 | $371 | $10 |
| Carvedilol | 25 | $288 | $12 |
| Cephalexin | 32 | $262 | $8 |
| Amlodipine Besylate | 22 | $257 | $12 |
| Isosorbide Mononitrate Er | 17 | $208 | $12 |
| Spironolactone | 22 | $200 | $9 |
2020: 11 drugs
| Pradaxa | 20 | $13,959 | $698 |
| Metoprolol | 33 | $712 | $22 |
| Amiodarone | 22 | $585 | $27 |
| Torsemide | 11 | $515 | $47 |
| Atorvastatin | 30 | $456 | $15 |
| Furosemide | 26 | $261 | $10 |
| Lisinopril | 21 | $252 | $12 |
| Metoprolol | 22 | $238 | $11 |
| Amlodipine Besylate | 19 | $189 | $10 |
| Carvedilol | 13 | $150 | $12 |
| Cephalexin | 13 | $107 | $8 |
2019: 1 drug
| Furosemide | 13 | $89 | $7 |
Money from drug and device companies
$255 in 2025
| 2025 | 2 | 3 | None | $255 |
| 2023 | 2 | 3 | None | $407 |
| 2022 | 2 | 2 | None | $259 |
| 2019 | 3 | 12 | None | $2,616 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 3 published payments
| Medtronic | Meals · 2025-08-15 | Cobalt Dr Mri Surescan | $57 |
| Heartflow | Meals · 2025-03-19 | Ffrct | $167 |
| Heartflow | Meals · 2025-02-18 | Ffrct | $31 |
See earlier years (2023, 2022, 2019)
2023: $407
| Medtronic | Selectsecure | $278 | 2 payments
|
| Boston Scientific | Watchman Flx | $129 | 1 payment
|
2022: $259
| Biotronik | Solia | $134 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $124 | 1 payment
|
2019: $2,616
| Medtronic Vascular | Advisa | $2,302 | 6 payments
|
| Medtronic | Adapta | $172 | 5 payments
|
| Abbott Laboratories | Mitra Clip System | $143 | 1 payment
|
Professional record
- NPI
- 1811331747
- Licence
- CA A134064California A134064: Current · expires 2027-01-31
- Trained
- University of California, San Francisco School of Medicine, 2013
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2013-04-22
- NPI last updated
- 2022-06-02
- NPI record certified
- 2022-06-02
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.